Login to Your Account



Galena Prices $35M Offering to fund Breast Cancer Drug

By Catherine Shaffer
Staff Writer

Monday, September 16, 2013
Galena Biopharma Inc. priced an underwritten public offering of 17.5 million units of stock at $2 per unit, for gross proceeds of $35 million. The funds will be used for commercialization of Abstral (fentanyl) sublingual tablets, and to support an ongoing Phase III trial of Neuvax.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription